Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Logos Capital

Investor type Hedge Fund
Founders Dr. Arsani William Edward Zhong Graham Walmsley

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 88
Average round size
info
The average size of a deal this fund participated in
$110M
Portfolio companies 80
Rounds per year 29.33
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 31
Key employees Soon
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Logos Capital:
Typical Co-investors
Logos Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Logos Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accord Ventures Chiyoda, Japan
Attestor Capital LLP England, London, United Kingdom
Baring Private Equity Asia China, Hong Kong, Hong Kong Island
China Yinhong -
Dynamic Balance Capital China, Jiangsu, Nanjing
FSD Africa Kenya, Nairobi, Nairobi Area
FueTrek Japan, Osaka, Osaka Prefecture
Gilbarco Veeder Root Greensboro, North Carolina, United States
H. C. Wainwright & Co. New York, New York, United States
Italia500 -
K2 Global California, San Francisco, United States
Kyoritsu Corporation Japan, Setagaya
Shanghai Chuangban Investment Management China, Shanghai
Shenzhen Hexie Fazhan Touzi China, Guangdong, Shenzhen
Sopartec -
Speedshield -
Supply Chain Labs Gurgaon, Haryana, India
The Drake Group Baar, Switzerland, Zug
ZG Ventures District of Columbia, United States, Washington

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Enliven Therapeutics

Biotechnology
Life Science
Therapeutics
$165M13 Oct 2022 Boulder, Colorado, United States

Immunic

Biotechnology
Life Science
Medical
Therapeutics
$60M10 Oct 2022 San Diego, California, United States

Immunovant

Biotechnology
Pharmaceutical
$75M04 Oct 2022 New York, New York, United States

Ventyx Biosciences

Biopharma
Biotechnology
$176M19 Sep 2022 Encinitas, California, United States

Elektrofi

Alternative Medicine
Biotechnology
Therapeutics
$40M13 Jun 2022 Boston, Massachusetts, United States

Grain

Software
Video Conferencing
$16M12 Apr 2022 California, United States

Triana Biomedicines

Biopharma
Biotechnology
Therapeutics
$110M06 Apr 2022 Waltham, Massachusetts, United States

Synthego

Biotechnology
Discovery Tools (Healthcare)
Genetics
Industrial Automation
Innovation Management
Life Science
Machine Learning
Software
$200M17 Feb 2022 Redwood City, California, United States

Parse Biosciences

Bioinformatics
Biotechnology
Genetics
Life Science
$41M15 Feb 2022 Seattle, Washington, United States
News
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Logos Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: